ovarian cancer

News

Lynparza on cusp of approval for advanced ovarian cancer

Breast cancer drug Lynparza (olaparib) is poised for EU approval for the first-line treatment of a certain type of metastatic ovarian cancer.

News

Merck and Pfizer stop third Bavencio ovarian cancer trial

Merck and Pfizer are discontinuing the Phase III JAVELIN Ovarian PARP 100 study evaluating Bavencio (avelumab) in advanced ovarian cancer, signalling yet more disappointment for the PD-L1 immuno

News

AZ/Merck & Co get new US use for ovarian cancer drug

After several disappointments this year AstraZeneca has ended 2018 on a positive note, gaining a new use for its ovarian cancer drug Lynparza in the US and a first approval in China for its

News

US regulator grants fast review for AZ ovarian cancer drug

The US Food and Drug Administration (FDA) has granted AstraZeneca priority review for its ovarian cancer drug Lynparza – and the company has also revealed positive results for its diabetes

Views & Analysis

The Frauenkirche is a church in the Bavarian city of Munich that serves as the cathedral of the Archdiocese of Munich and Freising and seat of its Archbishop.

ESMO round-up: Big win for AstraZeneca in ovarian cancer, an...

Several drugmakers announced significant trial findings at this week’s European Society for Medical Oncology (ESMO) conference in Munich.

News

AZ/Merck & Co's Lynparza scores huge ovarian cancer win

AstraZeneca and Merck & Co’s Lynparza (olaparib) has massively reduced the risk of BRCA-mutated ovarian cancer progressing in patients who have just been treated with chemo, in trial re

Lynparza on cusp of approval for advanced ovarian cancer

Merck and Pfizer stop third Bavencio ovarian cancer trial

AZ/Merck & Co get new US use for ovarian cancer drug

US regulator grants fast review for AZ ovarian cancer drug

ESMO round-up: Big win for AstraZeneca in ovarian cancer, an...

AZ/Merck & Co's Lynparza scores huge ovarian cancer win

Pfizer takes 25-valent Prevnar follow-up into phase 3

Discover a new era of healthcare panel engagement: Grounded ...

ovarian cancer

Editor's Picks